Trevi Therapeutics, Inc. Quarterly Deferred Tax Assets, Valuation Allowance in USD from Q4 2018 to Q4 2023

Taxonomy & unit
us-gaap: USD
Description
Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.
Summary
Trevi Therapeutics, Inc. quarterly Deferred Tax Assets, Valuation Allowance history and growth rate from Q4 2018 to Q4 2023.
  • Trevi Therapeutics, Inc. Deferred Tax Assets, Valuation Allowance for the quarter ending December 31, 2023 was $69.5M, a 13.8% increase year-over-year.
Deferred Tax Assets, Valuation Allowance, Quarterly (USD)
Deferred Tax Assets, Valuation Allowance, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q4 2023 $69.5M +$8.43M +13.8% Dec 31, 2023 10-K 2024-03-20
Q4 2022 $61.1M +$8.38M +15.9% Dec 31, 2022 10-K 2024-03-20
Q4 2021 $52.7M +$9.87M +23% Dec 31, 2021 10-K 2023-03-16
Q4 2020 $42.8M +$9.53M +28.6% Dec 31, 2020 10-K 2022-03-17
Q4 2019 $33.3M +$7.36M +28.4% Dec 31, 2019 10-K 2021-03-25
Q4 2018 $25.9M Dec 31, 2018 10-K 2020-03-16
* An asterisk sign (*) next to the value indicates that the value is likely invalid.